• Pitt
  • Health Sciences
  • UPMC
Regenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan Institute
  • Home
  • Our People
    • Faculty/Staff Bios
    • Core Faculty Publications
    • Administrative Resources
  • Our Technologies
  • About Us
    • Welcome
    • Video
    • Mission Statement
    • What Is Regenerative Medicine?
    • Executive Committee
    • Contact Us
    • Clinical Site
  • Our Research
    • Focus Areas
      • Tissue Engineering and Biomaterials
      • Cellular Therapies
      • Medical Devices and Artificial Organs
      • Clinical Translation
    • Matrix
    • Centers
    • Laboratories
    • Clinical Trials
    • Initiatives
  • Media
    • Current News
    • News Archive
    • Video
    • Podcasts
    • Newsletter
    • Grant of the Month
    • Publication of the Month
    • Media Contact
    • Video Links
  • Professional Development
    • Seminar Series
    • Special Events
    • Student Interest Groups
    • CATER
    • Post-Doctoral Opportunities
    • Career Opportunities
    • Wiegand Summer Internship
    • Admissions
    • Summer School
    • 2022 Scientific Retreat

Gene Therapy Treatment for Retinitis Pigmentosa Receives $58 Million Financing

    Home Current News Gene Therapy Treatment for Retinitis Pigmentosa Receives $58 Million Financing

    Gene Therapy Treatment for Retinitis Pigmentosa Receives $58 Million Financing

    By The McGowan Institute For Regenerative Medicine | Current News, Vision | Comments are Closed | 11 November, 2020 | 0

    sahel

    SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa (RP), the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.  McGowan Institute for Regenerative Medicine affiliated faculty member José-Alain Sahel, MD, Chair of the Department of Ophthalmology at the University of Pittsburgh School of

    Medicine, Director of the UPMC Eye Center, the Eye and Ear Foundation Chair of Ophthalmology, and Director of the Institut de la Vision (Sorbonne Universite, Inserm, CNRS, Paris), is a co-founder of SparingVision along with Thierry Léveillard, PhD.

    SparingVision recently announced a €44.5 million ($58.16 million) financing round. The round was led by 4BIO Capital and UPMC Enterprises and included Jeito Capital and Ysios Capital. In addition, current investors Bpifrance and Foundation Fighting Blindness participated in the round.

    Proceeds from the financing will be primarily used to advance the development of SparingVision’s breakthrough treatment SPVN06 for the mutation-agnostic treatment of RP. Most notably the funding will support SparingVision’s GMP activities (including the manufacturing of a first clinical batch of the product, currently ongoing), the IND/CTA regulatory activities and the conduct of a first-in-man study, scheduled to start in 2021. SparingVision also intends to further expand its management team and commence operations in the US.

    “SparingVision’s neuroprotective approach, which I started working on some 20 years ago at Institut de la Vision, has all the attributes of a winning gene therapy solution for retinitis pigmentosa patients in desperate need of a universal therapeutic option. I am looking forward to helping Stéphane [Boissel, SparingVision’s President and Chief Executive Officer] and the team best position SPVN06 for clinical development up to regulatory licensing,” said Dr. Sahel.

    SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy consisting of one neurotrophic factor and one oxidative stress reducing enzyme which, acting synergistically, aim to slow or stop the degeneration of photoreceptors. Loss of photoreceptors leads to blindness in RP, one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved for RP patients independently of their genetic background.

    Read more…

    SparingVision News Release

    Fierce Biotech

    Pittsburgh Post-Gazette

    Print Friendly, PDF & Email
    No tags.

    The McGowan Institute For Regenerative Medicine

    More posts by The McGowan Institute For Regenerative Medicine

    • site map
    • links
    • contact
    • subscribe to our newsletter
    © Copyright 2021 McGowan Institute for Regenerative Medicine
    A program of the University of Pittsburgh and the University of Pittsburgh Medical Center
    • Home
    • Our People
      • Faculty/Staff Bios
      • Core Faculty Publications
      • Administrative Resources
    • Our Technologies
    • About Us
      • Welcome
      • Video
      • Mission Statement
      • What Is Regenerative Medicine?
      • Executive Committee
      • Contact Us
      • Clinical Site
    • Our Research
      • Focus Areas
        • Tissue Engineering and Biomaterials
        • Cellular Therapies
        • Medical Devices and Artificial Organs
        • Clinical Translation
      • Matrix
      • Centers
      • Laboratories
      • Clinical Trials
      • Initiatives
    • Media
      • Current News
      • News Archive
      • Video
      • Podcasts
      • Newsletter
      • Grant of the Month
      • Publication of the Month
      • Media Contact
      • Video Links
    • Professional Development
      • Seminar Series
      • Special Events
      • Student Interest Groups
      • CATER
      • Post-Doctoral Opportunities
      • Career Opportunities
      • Wiegand Summer Internship
      • Admissions
      • Summer School
      • 2022 Scientific Retreat
    Regenerative Medicine at the McGowan Institute